4.10
-0.02 (-0.36%)
Market Trend
Short Term | Medium Term | ||
Industry | Biotechnology (US) | Bearish | Bullish |
Biotechnology (Global) | Bearish | Bullish | |
Stock | AbCellera Biologics Inc. | Bearish | Bearish |
Analyst Consensus
2 Buy
Avg. Price @ Call: 4.33
AbCellera Biologics Inc is an antibody discovery and development engine that’s specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company’s experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program. |
|
Sector | Healthcare |
Industry | Biotechnology |
Investment Style | Small Value |
Ownership
Name | Date | Shares Held |
---|---|---|
Founders Fund Vii Management, Llc | 31 Dec 2023 | 3,773,530 |
Guardian Capital Advisors Lp | 31 Dec 2023 | 1,786,414 |
52 Weeks Range |
3.62 - 8.05
|
|
Price Target Range | ||
High | 17.00 (Stifel, 315.14%) | Buy |
Median | 12.00 (193.04%) | |
Low | 7.00 (Keybanc, 70.94%) | Buy |
Average | 12.00 (193.04%) | |
Total | 2 Buy |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
Keybanc | 08 May 2024 | 7.00 (70.94%) | Buy | 3.84 |
Stifel | 21 Feb 2024 | 17.00 (315.14%) | Buy | 4.81 |
No data within this time range.
Date | Type | Details |
---|---|---|
07 May 2024 | Announcement | AbCellera Reports Q1 2024 Business Results |
01 May 2024 | Announcement | AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies |
08 Apr 2024 | Announcement | AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024 |
03 Apr 2024 | Announcement | AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024 |
19 Mar 2024 | Announcement | AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024 |
11 Mar 2024 | Announcement | AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions |
05 Mar 2024 | Announcement | AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024 |
23 Feb 2024 | Announcement | AbCellera Announces Resignation of Board Member |
22 Feb 2024 | Announcement | AbCellera to Present at Upcoming Investor Conferences in March |
20 Feb 2024 | Announcement | AbCellera Reports Full Year 2023 Business Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2024 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |